FIBROMYALGIA SYNDROME: CLINICAL PICTURE, DIAGNOSIS AND TREATMENT
Keywords:
fibromyalgia, symptoms, therapy, disease, treatment, diagnosis, medicine, pain, symptom complexAbstract
The article is devoted to the syndrome of fibromyalgia - one of the most common rheumatological diseases. Fibromyalgia is one of the most challenging problems in clinical practice. Discussion issues are the issues of its clinical symptom formation, nosological independence and choice priority treatment methods. To date, the number of randomized trials on the effectiveness of the treatment of fibromyalgia has increased significantly. This made it possible to identify priority areas in the treatment of the disease. Detailed information on diagnosis and treatment is provided in the research.
References
Arnold L.M., Rosen A., Pritchett Y.L. et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder // Pain. 2005; 119 (1–3): P. 5–15.
Bennett M.I, Tai Y.M. Intravenous lignocaine in the management of primary fibromyalgia syndrome // Int J Clin Pharmacol Res. 1995; 15 (3): P. 115–119.
Crofford L.J., Rowbotham M.C., Mease P.J. et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial // Arthritis Rheum. 2005; 52 (4): P.1264–1273.
Crofford L. J., Mease P. J., Simpson S. L. et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-months, double-blind, placebo-controlled trial with pregabalin // Pain. 2008; 136: P.419–431.
Fishbain D.A., Cutler R. B., Rosomoff H. L. et al. Clonazepam open clinical treatment trial for myofascial syndrome associated chronic pain // Pain Med. 2000; 1 (4): P. 332–339.
Jones K. D., Adams D., Winters-Stone K. et al. A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988–2005) // Health Qual Life Outcomes. 2006; 4: P. 67–73.
Hauser W., Bernardy K., Uceyler N. et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials // Pain. 2009; 145 (1–2): P.69–81.
Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment // J Rheumatol. 2005; 32, suppl. 75: P. 6–21.
Mease P. J., ClauwD. J., Gendreau R. M. et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial // J Rheumatol. 2009; 36 (2): ;P. 398–409.
Russell I. J., Fletcher E. M., Michalek J. E. et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study // Arthritis Rheum. 1991; 34 (5): P. 552–556.
Straube S., Derry S., Moore R., McQuay H. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports // Rheumatology. 2010; 49: P. 706–715.
Tofferi J. K., Jackson J. L., O’Malley P. G. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis // Arthritis Rheum. 2004; 51 (1): P. 9–13.
Xaio Y., Michalek J. E., Russell I. J. Effects of tizanidine on cerebrospinal fluid substance P in patients with fibromyalgia. In: Saper JR, editor. Alpha-2 adrenergic agonists: evidence and experience examined. Worcester, UK: The Royal Society of Medicine Press, The Trinity Press, 2002: P. 23–28.
